Sanofi sticks to plan under pressure from pandemic

5 February 2021

French pharma major Sanofi (Euronext: SAN) has reported final quarter 2020 sales of 9.4 billion euros ($11.3 billion), bringing the year’s total to 36 billion euros, up 3.3%.

Quarterly revenues relied heavily on a strong performance from the interleukin (IL)-4 and IL-13 blocker Dupixent (dupilumab), with sales soaring to 982 million euros, an increase of 54%.

Nonetheless, the overall result fell short of many analysts’ expectations, with the FT consensus forecast having come in at 9.6 billion euros for the quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK